Apotex

Apotex, a Pharmaceutical Preparation Manufacturing company headquartered in CA, reported its most recent carbon emissions for 2023. In 2023, Apotex's Scope 1 emissions were approximately 40,219,000 kg CO2e, and its Scope 2 emissions were approximately 15,572,000 kg CO2e. The total disclosed emissions for Scope 1 and 2 in 2023 were approximately 55,791,000 kg CO2e.

Looking back, in 2022, Apotex recorded Scope 1 emissions of about 42,950,000 kg CO2e and Scope 2 emissions of about 16,173,000 kg CO2e, totalling approximately 59,123,000 kg CO2e. In 2021, the company reported Scope 1 emissions at roughly 42,612,000 kg CO2e and Scope 2 emissions at approximately 18,969,000 kg CO2e, a combined total of about 61,581,000 kg CO2e.

For 2020, Apotex's Scope 1 emissions were approximately 42,120,000 kg CO2e, with Scope 2 emissions at about 16,613,000 kg CO2e, bringing the total to approximately 58,733,000 kg CO2e. In 2019, Scope 1 emissions were around 45,097,000 kg CO2e, and Scope 2 emissions were approximately 17,349,000 kg CO2e, for a total of about 62,446,000 kg CO2e. In 2018, Scope 1 emissions totalled approximately 44,817,000 kg CO2e, and Scope 2 emissions were about 20,870,000 kg CO2e, leading to a combined total of approximately 65,687,000 kg CO2e.

Apotex acknowledges the need for decarbonisation and is actively evaluating potential pathways to achieve this. As part of its near-term strategy (2023-2025), the company is undertaking an evaluation process to inform the specifics and timeline for setting rigorous emissions reduction targets for both Scope 1 and Scope 2. Apotex's emissions data is cascaded from its corporate family, Apotex Inc., as a current subsidiary.